Johnson & Johnson (NYSE:JNJ)
Stock Price:
$154.36
-0.98
(%)
Updated
Dec 8, 2023 09:00 PM GMT+0000
| Market Cap | 371.73B |
|---|---|
| Revenue | 95.33B |
| Gross Profit | 64.36B |
| Shares Out | 2.41B |
| EPS (ttm) | 13.26 |
| PE Ratio | 11.0234 |
| Forward PE | 15.0808 |
| Dividend Rate (ttm) | 4.6472 |
| Dividend Yield | 0.0293 |
| Trading Day | Dec 11 |
|---|---|
| Last Price | $154.36 |
| Previous Close | $155.40 |
| Change ($) | -0.98 |
| Change (%) | -0.00631% |
| Day's Open | $155.76 |
| Day's Range | $154.78 - $155.76 |
| Day's Volume | 6.25M |
| 52 Week Range | $143.8 - $175.71 |
About Johnson & Johnson
NYSE:JNJ stock is currently trading at $154.42 as of 09:00 PM UTC, Dec 8, 2023. Use the financials tab to find out more about Johnson & Johnson's key financial metrics and recent earnings reports, or track its share price in real time on the chart tab. If you would like to buy shares in Johnson & Johnson, our detailed guide explains how to buy Johnson & Johnson stock.
News
Quick info
Country
United States
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Employees
152,700
CEO
Alex Gorsky
Address
1 Johnson And Johnson Plz
New Brunswick
New Jersey
08933-0001
New Brunswick
New Jersey
08933-0001
Phone
17325242455
Website
https://www.jnj.com/
Ticker Symbol
JNJ
Exchange
NEW YORK STOCK EXCHANGE INC.
Reporting Currency
USD
Johnson & Johnson income statements (2023)
| October 2023 | July 2023 | April 2023 | |
|---|---|---|---|
| Total Revenue | 21.35B | 25.53B | 24.75B |
| Cost of Revenue | 6.61B | 8.21B | 8.40B |
| Gross Profit | 14.75B | 17.32B | 16.35B |
| Research & Development | 3.45B | 3.83B | 3.56B |
| Selling General & Admin | 5.40B | 6.67B | 6.14B |
| Operating Expense | N.A | N.A | N.A |
| Operating Income | 5.90B | 6.82B | 6.65B |
| Other Income Expense Net | 0 | 0 | 0 |
| EBIT | 5.90B | 6.82B | 6.65B |
| Interest Income | 0 | 0 | 0 |
| Pretax Income | 5.22B | 6.76B | 0 |
| Income Tax | 0.91B | 1.62B | 0 |
| Minority Interest | 0 | 0 | 0 |
| Net Income | 26.03B | 5.14B | 0 |
| Net Income Basic | 26.03B | 5.14B | 0 |
Johnson & Johnson income statements (2022)
| February 2023 | October 2022 | July 2022 | |
|---|---|---|---|
| Total Revenue | 23.71B | 23.79B | 24.02B |
| Cost of Revenue | 7.77B | 7.81B | 7.92B |
| Gross Profit | 15.94B | 15.98B | 16.10B |
| Research & Development | 3.84B | 3.60B | 3.70B |
| Selling General & Admin | 6.51B | 6.09B | 6.23B |
| Operating Expense | N.A | N.A | N.A |
| Operating Income | 5.59B | 6.30B | 6.17B |
| Other Income Expense Net | 0 | 0 | 0 |
| EBIT | 5.59B | 6.30B | 6.17B |
| Interest Income | 0 | 0 | 0 |
| Pretax Income | 4.20B | 5.82B | 5.84B |
| Income Tax | 681M | 1.36B | 1.03B |
| Minority Interest | 0 | 0 | 0 |
| Net Income | 3.52B | 4.46B | 4.81B |
| Net Income Basic | 3.52B | 4.46B | 4.81B |
Johnson & Johnson balance sheet (2023)
| October 2023 | July 2023 | April 2023 | February 2023 | |
|---|---|---|---|---|
| Current Cash | 23.51B | 28.51B | 24.61B | 23.52B |
| Receivables | 14.80B | 16.78B | 16.35B | 16.16B |
| Inventory | 11.20B | 12.89B | 12.81B | 12.48B |
| Current Assets | 53.70B | 60.57B | 64.39B | 55.29B |
| Other Current Assets | 4.20B | 2.40B | 2.92B | 3.13B |
| Short Term Investments | 4.20B | 2.40B | 2.92B | 3.13B |
| Long Term Investments | 112.36B | 131.12B | 131.58B | 132.08B |
| Property/Plant Equipment | 18.82B | 20.58B | 20.17B | 19.80B |
| Good Will | 36.12B | 45.44B | 45.58B | 45.23B |
| Intangible Assets | 35.02B | 46.25B | 47.45B | 48.33B |
| Tangible Assets (Net) | 83M | 0 | 0 | 0 |
| Other Assets | 13.13B | 10.08B | 9.57B | 9.03B |
| Total Assets | 166.06B | 191.69B | 195.97B | 187.38B |
| Accounts Payable | 8.36B | 10.44B | 9.91B | 11.70B |
| Other Current Liabilities | 32.15B | 32.03B | 32.49B | 31.33B |
| Total Current Liabilities | 44.37B | 54.17B | 60.37B | 55.80B |
| Total Liabilities | 94.83B | 116.54B | 125.10B | 110.57B |
| Long Term Debt | 26.05B | 33.90B | 34.93B | 26.89B |
| Current Long Term Debt | 3.87B | 11.70B | 17.98B | 12.77B |
| Minority Interest | 0 | 1.26B | 0 | 0 |
| Common Stock | 2.52B | 2.60B | 2.61B | 2.61B |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Retained Earnings | 152.54B | 129.38B | 124.56B | 128.35B |
| Capital Surplus | N.A | N.A | N.A | N.A |
| Shareholder Equity | 71.23B | 75.15B | 70.87B | 76.80B |
| Other Liabilities | 21.79B | 23.58B | 25.38B | 21.51B |
Johnson & Johnson balance sheet (2022)
| October 2022 | July 2022 | |
|---|---|---|
| Current Cash | 34.08B | 32.57B |
| Receivables | 15.89B | 16.14B |
| Inventory | 11.68B | 11.44B |
| Current Assets | 65.24B | 63.85B |
| Other Current Assets | 3.59B | 3.70B |
| Short Term Investments | 3.59B | 3.70B |
| Long Term Investments | 109.89B | 113.88B |
| Property/Plant Equipment | 18.15B | 18.35B |
| Good Will | 33.38B | 34.17B |
| Intangible Assets | 40.34B | 42.41B |
| Tangible Assets (Net) | 880M | 0 |
| Other Assets | 8.63B | 9.44B |
| Total Assets | 175.12B | 177.72B |
| Accounts Payable | 10.15B | 9.77B |
| Other Current Liabilities | 30.97B | 30.75B |
| Total Current Liabilities | 45.54B | 44.82B |
| Total Liabilities | 100.53B | 101.37B |
| Long Term Debt | 27.60B | 28.29B |
| Current Long Term Debt | 4.42B | 4.31B |
| Minority Interest | 0 | 0 |
| Common Stock | 2.63B | 2.63B |
| Treasury Stock | 0 | 0 |
| Retained Earnings | 127.92B | 126.22B |
| Capital Surplus | N.A | N.A |
| Shareholder Equity | 74.60B | 76.36B |
| Other Liabilities | 22.43B | 23.24B |
Johnson & Johnson cash flow (2023)
| October 2023 | July 2023 | April 2023 | February 2023 | October 2022 | July 2022 | |
|---|---|---|---|---|---|---|
| Net Income | 26.03B | 5.14B | 0 | 3.52B | 4.46B | 4.81B |
| Depreciation | 1.83B | 1.93B | 1.88B | 1.77B | 1.69B | 1.74B |
| Changes in Receivables | 14.80B | 16.78B | 16.35B | 16.16B | 15.89B | 16.14B |
| Changes in Inventories | 11.20B | 12.89B | 12.81B | 12.48B | 11.68B | 11.44B |
| Cash Change | 23.51B | 28.51B | 24.61B | 23.52B | 34.08B | 32.57B |
| Cash Flow | 7.49B | 4.18B | 3.26B | 5.35B | 6.28B | 5.58B |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | N.A | N.A | N.A | N.A | N.A | N.A |
| Investing Activity (other) | N.A | N.A | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | 2.54B | 0 | 3.32B | 0 | 0 | 0 |
| Dividends Paid | N.A | N.A | N.A | N.A | N.A | N.A |
| Net Borrowings | 2.21B | 14.70B | 25.37B | 13.01B | 0 | 0 |
| Other Financing Cash Flows | N.A | N.A | N.A | N.A | N.A | N.A |
| Cash Flow Financing | 0 | 0 | 6.14B | 1.70B | 0 | 0 |
| Exchange Rate Effect | N.A | N.A | N.A | N.A | N.A | N.A |
Johnson & Johnson dividends
| Ex date | Payment date | Record date | Declared date | Amount | Description | Frequency |
|---|---|---|---|---|---|---|
| 20-11-2023 | 05-12-2023 | 21-11-2023 | 19-10-2023 | 1.19 | Ordinary Shares | Quarterly |
| 25-08-2023 | 07-09-2023 | 28-08-2023 | 20-07-2023 | 1.19 | Ordinary Shares | Quarterly |
| 22-05-2023 | 06-06-2023 | 23-05-2023 | 18-04-2023 | 1.19 | Ordinary Shares | Quarterly |
| 17-02-2023 | 07-03-2023 | 21-02-2023 | 03-01-2023 | 1.13 | Ordinary Shares | Quarterly |
| 21-11-2022 | 06-12-2022 | 22-11-2022 | 19-10-2022 | 1.13 | Ordinary Shares | Quarterly |
| 22-08-2022 | 06-09-2022 | 23-08-2022 | 18-07-2022 | 1.13 | Ordinary Shares | Quarterly |
Total Valuation
Johnson & Johnson has a market cap or net worth of $371.73 billion. The enterprise value is $388.08 billion.
Market Cap
371.73B
Enterprise Value
388.08B
Important Dates
Earnings Date
Jan 23, 2024
Ex-Dividend Date
n.a
Share Statistics
Johnson & Johnson has 2.41 billion shares outstanding.
Shares Outstanding
2.41B
Valuation Ratios
The trailing PE ratio is 11.0234 and the forward PE ratio is 15.0808. Johnson & Johnson's PEG ratio is 0.1301.
PE Ratio
11.0234
Forward PE
15.0808
PS Ratio
4.0000
PB Ratio
5.3600
PEG Ratio
0.1301
Stock Price Statistics
The stock price has decreased by -0.0862%. The beta is 0.3417, so Johnson & Johnson's price volatility has been lower than the market average.
Beta (1Y)
0.3417
52-Week Price Change
-0.0862%
50-Day Moving Average
150.00
200-Day Moving Average
158.00
Average Volume (30 Days)
6.84M
Income Statement
In the last 12 months, Johnson & Johnson had revenue of $95.33 billion and earned $64.36 billion in profits. Earnings per share was $13.26.
Revenue
95.33B
Gross Profit
64.36B
EBITDA
32.38B
Earnings per Share
13.26
About
Country
United States
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Employees
152,700
CEO
Alex Gorsky
Address
1 Johnson And Johnson Plz
New Brunswick
New Jersey
08933-0001
New Brunswick
New Jersey
08933-0001
Phone
17325242455
Website
https://www.jnj.com/
Ticker Symbol
JNJ
Exchange
NEW YORK STOCK EXCHANGE INC.
Reporting Currency
USD
Key Executives
Mccoy Sherilyn S
Member, Executive Committee
Fasolo Peter
VP, Global Human Resources
Kapusta Ronald A
Controller, CAO
Broadhurst Vanessa
EVP, Global Corp Aff.
Pruden Gary J
Exec VP, WW Chair, Med Devices
Duato Joaquin
Vice Chair, Exec Committee
Peterson Sandra E
Group Worldwide Chairman
Mesquita Jorge S.
Exec VP, WW Chair, Consumer
Weldon William C
Chairman/CEO
Valeriani Nicholas J
VP, Strategy & Growth
Caruso Dominic J
Chief Financial Officer
Poon Christine A
Vice Chairman
Hait William
haitpoa1.txt
Title: Executive Vice President, Chief External Innovation, Medical Safety and Global Public Health Officer
Mammen Mathai
EVP, Pharm, R&D
Foster-cheek Kaye I
VP, Human Resources
Goggins Colleen A
Member, Executive Committee
Gorsky Alex
Member, Executive Committee